|
1
|
Corey SJ, Minden MD, Barber DL, Kantarjian
H, Wang JC and Schimmer AD: Myelodysplastic syndromes: the
complexity of stem-cell diseases. Nat Rev Cancer. 7:118–129. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wouters BJ and Delwel R: Epigenetics and
approaches to targeted epigenetic therapy in acute myeloid
leukemia. Blood. 127:42–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shih AH, Abdel-Wahab O, Patel JP and
Levine RL: The role of mutations in epigenetic regulators in
myeloid malignancies. Nat Rev Cancer. 12:599–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haase D, Germing U, Schanz J, Pfeilstöcker
M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R,
Giagounidis AA, et al: New insights into the prognostic impact of
the karyotype in MDS and correlation with subtypes: evidence from a
core dataset of 2124 patients. Blood. 110:4385–4395. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bernasconi P, Klersy C, Boni M, Cavigliano
PM, Calatroni S, Giardini I, Rocca B, Zappatore R, Caresana M,
Dambruoso I, et al: World Health Organization classification in
combination with cytogenetic markers improves the prognostic
stratification of patients with de novo primary myelodysplastic
syndromes. Br J Haematol. 137:193–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schanz J, Steidl C, Fonatsch C,
Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B,
Giagounidis A, Aul C, et al: Coalesced multicentric analysis of
2,351 patients with myelodysplastic syndromes indicates an
underestimation of poor-risk cytogenetics of myelodysplastic
syndromes in the international prognostic scoring system. J Clin
Oncol. 29:1963–1970. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maciejewski JP and Mufti GJ: Whole genome
scanning as a cytogenetic tool in hematologic malignancies. Blood.
112:965–974. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kralovics R: Genetic complexity of
myeloproliferative neoplasms. Leukemia. 22:1841–1848. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang L, Fidler C, Nadig N, Giagounidis A,
Della Porta MG, Malcovati L, Killick S, Gattermann N, Aul C,
Boultwood J, et al: Genome-wide analysis of copy number changes and
loss of heterozygosity in myelodysplastic syndrome with del(5q)
using high-density single nucleotide polymorphism arrays.
Haematologica. 93:994–1000. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sapiro R, Kostetskii I, Olds-Clarke P,
Gerton GL, Radice GL and Strauss JF III: Male infertility, impaired
sperm motility, and hydrocephalus in mice deficient in
sperm-associated antigen 6. Mol Cell Biol. 22:6298–6305. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steinbach D, Schramm A, Eggert A, Onda M,
Dawczynski K, Rump A, Pastan I, Wittig S, Pfaffendorf N, Voigt A,
et al: Identification of a set of seven genes for the monitoring of
minimal residual disease in pediatric acute myeloid leukemia. Clin
Cancer Res. 12:2434–2441. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mulaw MA, Krause A, Deshpande AJ, Krause
LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig
WD, et al: CALM/AF10-positive leukemias show upregulation of
genes involved in chromatin assembly and DNA repair processes and
of genes adjacent to the breakpoint at 10p12. Leukemia.
26:1012–1019. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang B, Wang L, Luo X, Chen L, Yang Z and
Liu L: SPAG6 silencing inhibits the growth of the malignant myeloid
cell lines SKM-1 and K562 via activating p53 and caspase
activation-dependent apoptosis. Int J Oncol. 46:649–656.
2015.PubMed/NCBI
|
|
14
|
Kerbauy DB and Deeg HJ: Apoptosis and
antiapoptotic mechanisms in the progression of myelodysplastic
syndrome. Exp Hematol. 35:1739–1746. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Griffith TS and Lynch DH: TRAIL: a
molecule with multiple receptors and control mechanisms. Curr Opin
Immunol. 10:559–563. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kranz D and Boutros M: A synthetic lethal
screen identifies FAT1 as an antagonist of caspase-8 in extrinsic
apoptosis. EMBO J. 33:181–197. 2014.PubMed/NCBI
|
|
17
|
Igney FH and Krammer PH: Death and
anti-death: tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martin GS: Cell signaling and cancer.
Cancer Cell. 4:167–174. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zang DY, Goodwin RG, Loken MR, Bryant E
and Deeg HJ: Expression of tumor necrosis factor-related
apoptosis-inducing ligand, Apo2L, and its receptors in
myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood.
98:3058–3065. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Benesch M, Platzbecker U, Ward J, Deeg HJ
and Leisenring W: Expression of FLIP(Long) and FLIP(Short) in bone
marrow mononuclear and CD34+ cells in patients with
myelodysplastic syndrome: correlation with apoptosis. Leukemia.
17:2460–2466. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamamoto K, Abe S, Nakagawa Y, Suzuki K,
Hasegawa M, Inoue M, Kurata M, Hirokawa K and Kitagawa M:
Expression of IAP family proteins in myelodysplastic syndromes
transforming to overt leukemia. Leuk Res. 28:1203–1211. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Parker JE, Mufti GJ, Rasool F, Mijovic A,
Devereux S and Pagliuca A: The role of apoptosis, proliferation,
and the Bcl-2-related proteins in the myelodysplastic syndromes and
acute myeloid leukemia secondary to MDS. Blood. 96:3932–3938.
2000.PubMed/NCBI
|
|
23
|
Zhang Z, Jones BH, Tang W, Moss SB, Wei Z,
Ho C, Pollack M, Horowitz E, Bennett J, Baker ME, et al: Dissecting
the axoneme interactome: the mammalian orthologue of
Chlamydomonas PF6 interacts with sperm-associated antigen 6,
the mammalian orthologue of Chlamydomonas PF16. Mol Cell
Proteomics. 4:914–923. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pearson CG, Giddings TH Jr and Winey M:
Basal body components exhibit differential protein dynamics during
nascent basal body assembly. Mol Biol Cell. 20:904–914. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Steinbach D, Bader P, Willasch A,
Bartholomae S, Debatin KM, Zimmermann M, Creutzig U, Reinhardt D
and Gruhn B: Prospective validation of a new method of monitoring
minimal residual disease in childhood acute myelogenous leukemia.
Clin Cancer Res. 21:1353–1359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Silina K, Zayakin P, Kalnina Z, Ivanova L,
Meistere I, Endzelins E, Abols A, Stengrēvics A, Leja M, Ducena K,
et al: Sperm-associated antigens as targets for cancer
immunotherapy: expression pattern and humoral immune response in
cancer patients. J Immunother. 34:28–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ashkenazi A and Dixit VM: Death receptors:
signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scaffidi C, Kirchhoff S, Krammer PH and
Peter ME: Apoptosis signaling in lymphocytes. Curr Opin Immunol.
11:277–285. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gonzalvez F and Ashkenazi A: New insights
into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29:4752–4765.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of
BID by caspase 8 mediates the mitochondrial damage in the Fas
pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu X, Yue P, Khuri FR and Sun SY: p53
upregulates death receptor 4 expression through an intronic p53
binding site. Cancer Res. 64:5078–5083. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takimoto R and El-Deiry WS: Wild-type p53
transactivates the KILLER/DR5 gene through an intronic
sequence-specific DNA-binding site. Oncogene. 19:1735–1743. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Henry H, Thomas A, Shen Y and White E:
Regulation of the mitochondrial checkpoint in p53-mediated
apoptosis confers resistance to cell death. Oncogene. 21:748–760.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Falschlehner C, Emmerich CH, Gerlach B and
Walczak H: TRAIL signalling: decisions between life and death. Int
J Biochem Cell Biol. 39:1462–1475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, et al: Safety and antitumor activity of recombinant soluble Apo2
ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wen J, Ramadevi N, Nguyen D, Perkins C,
Worthington E and Bhalla K: Antileukemic drugs increase death
receptor 5 levels and enhance Apo-2L-induced apoptosis of human
acute leukemia cells. Blood. 96:3900–3906. 2000.PubMed/NCBI
|
